39.15
2.23%
-0.995
전일 마감가:
$40.14
열려 있는:
$40.18
하루 거래량:
1.10M
Relative Volume:
0.94
시가총액:
$7.30B
수익:
$455.99M
순이익/손실:
$-285.01M
주가수익비율:
-12.01
EPS:
-3.26
순현금흐름:
$-164.61M
1주 성능:
-1.62%
1개월 성능:
-9.68%
6개월 성능:
-8.65%
1년 성능:
-31.45%
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
LEGN | 39.14 | 7.30B | 455.99M | -285.01M | -164.61M | -3.26 |
VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 747.25 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 245.84 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-12-19 | 개시 | Scotiabank | Sector Perform |
2023-11-06 | 개시 | Goldman | Buy |
2023-05-25 | 개시 | William Blair | Mkt Perform |
2023-05-22 | 개시 | Daiwa Securities | Buy |
2023-03-29 | 개시 | H.C. Wainwright | Buy |
2023-03-24 | 개시 | RBC Capital Mkts | Outperform |
2022-12-06 | 개시 | UBS | Buy |
2022-11-02 | 개시 | Evercore ISI | Outperform |
2022-11-01 | 개시 | Cowen | Outperform |
2022-10-31 | 개시 | Guggenheim | Neutral |
2022-06-17 | 개시 | BMO Capital Markets | Outperform |
2022-03-15 | 개시 | Barclays | Overweight |
2022-01-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-12-21 | 개시 | Piper Sandler | Overweight |
2021-05-18 | 개시 | BTIG Research | Buy |
2020-07-01 | 개시 | JP Morgan | Overweight |
2020-07-01 | 개시 | Jefferies | Buy |
2020-06-30 | 개시 | Morgan Stanley | Overweight |
모두보기
Legend Biotech Corp Adr 주식(LEGN)의 최신 뉴스
Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com
Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com
Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Legend Biotech appoints new President for CARVYKTI - Investing.com
Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance
Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register
Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India
Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India
Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily
Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily
Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily
BMO maintains steady target on Legend Biotech on strong sales - Investing.com
BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa
Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex
Legend Biotech Corp ADR’s results are impressive - US Post News
UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers By Investing.com - Investing.com UK
Legend Biotech maintains shares price target on steady Q3 growth - Investing.com
Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle
Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex
Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com
Legend Biotech Corp ADR (LEGN) is a good investment, but the stock may be overvalued - US Post News
Redburn sees growth potential for Legend Biotech stock on Carvykti demand - Investing.com
Does Legend Biotech Corp ADR (LEGN) offer a good opportunity for investors? - SETE News
Legend Biotech stock maintains positive outlook with new Philadelphia R&D facility - Investing.com
Upward Trajectory: Legend Biotech Corp ADR (LEGN) Posts a Gaine, Closing at 48.68 - The Dwinnex
Legend Biotech Corp ADR (LEGN) stock analysis: A simple moving average approach - US Post News
You might want to take a look at Legend Biotech Corp ADR (LEGN) now - SETE News
Legend Biotech shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
BMO maintains Outperform rating on Legend Biotech shares on Carvykti data - Investing.com India
Legend Biotech shares maintain Buy rating from H.C. Wainwright - Investing.com India
Legend Biotech's SWOT analysis: carvykti success drives stock potential - Investing.com
Legend Biotech reiterates stock target, overweight on Phase III data - Investing.com
Legend Biotech stock poised for growth with compelling data on Carvykti - Investing.com
Legend Biotech Corp ADR (LEGN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Can you now get a good deal on Legend Biotech Corp ADR’s shares? - US Post News
There is no doubt that Legend Biotech Corp ADR (LEGN) ticks all the boxes. - SETE News
Closing Bell Recap: Legend Biotech Corp ADR (LEGN) Ends at 45.92, Reflecting a -5.38 Downturn - The Dwinnex
Analytical Lens: Exploring Legend Biotech Corp ADR (LEGN)’s Financial Story Through Ratios - The Dwinnex
What was Legend Biotech Corp ADR (LEGN)’s performance in the last session? - US Post News
European Investors Can Invest in the Future of U.S. Healthcare With This ETF - Trackinsight
Legend Biotech Corp Adr (LEGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):